Surgical Site Infection
Some of the information contained on this webpage pertains to products, indications for use of products and/or therapies that are only available outside the United States and have not been approved or cleared for marketing by the United States Food & Drug Administration.
Bielecki TM, Gazdzik TS, Arendt J, et al. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances. J Bone Joint Surg Br 2007;89(3):417-20.
A new paper has been published in the British JBJS regarding autologous platelet gel and its effect on infection.1
Highlights:20 healthy humans donated 54ml of blood
Using the GPS® System to produce autologous PRP.
An in-vitro study was conducted to determine the antibacterial effects of autologous platelet gel on different bacterial strains.
| Bacterial Strains Tested | % of Surgical Site Infections2-4 |
| MSSA (methicillin-sensitive Staphylococcus aureus) | 30.3-45.1% |
| MRSA (methicillin-resistant Staphylococcus aureus) | 30.3-45.1% |
| E-Coli (Escherichia coli,Extended Spectrum Beta Lactamase) | 10.9-12.4% |
| ESBL (Klebsiella pneumoniae) | 10.9-12.4% |
| Enterococcus faecalis | 4.1-10.2% |
| Pseudomonas aeruginosa | 3.3-18.2% |
Agar plates were coated with different bacterial strains and treated with either a thrombin control or a thrombin-PRP combination. After 16-18 hours of incubation, the zones of inhibition around the treated areas were evaluated regarding the antimicrobial activity.
Results“Platelet-rich gel dramatically inhibited the growth of MSSA”1
“It was also active against MRSA and E. Coli”1
These are the most common bacteria strains associated with surgical site infections.2-4
The results of this study suggest the use of autologous platelet concentrate may reduce the incidence of MSSA, MRSA and E. Coli acquired infections during primary surgical closure. Additionally, this work may provide insight into the mechanism of action regarding the reduction in post-operative infections following median sternotomies reported by Khalafi.6
GPS is a trademark of Biomet Manufacturing Corp.
References
- Bielecki TM, et al. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances. JBJS Br 2007;89-B:417-420.
- Cantion CA, et al. Significant pathogens isolated from surgical site infections at a community hospital in the Midwest. Am J Infect Control 2006;34(8):526-9.
- Cheadle WG. Risk factors for surgical site infection. Surg Infect (Larchmt). 2006;7(Suppl 1):S7-11.
- Taylor MD, et al. Methicillin-Resistant Staphlococcus aureus infections in vascular surgery: increasing prevalence. Surgical Infections 2004;5(2):180-187.
- Sharma M, Berriel-Cass D, Baran J. Sternal surgical-site infection following coronary artery bypass graft: prevalence, microbiology, and complications during a 42-month period. Infect Control Hosp Epidemiol 2004;25:468-71.
- 6th Annual Hellenic Cardiac Surgery Congress, Thessaloniki, Greece, November, 2006.
As the manufacturer of biologic products, Biomet Biologics, Inc., does not practice medicine and cannot advise patients on medical care. This web site is intended for general product information only, and Biomet Biologics, Inc., should not be contacted for medical advice or questions regarding diagnosis or treatment. All medical treatment questions should be directed to a licensed physician.